ATOSSA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.61 USD | 0.00% |
|
-4.73% | +82.95% |
| 05-15 | Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial | MT |
| 05-15 | Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. | Other Biotechnology & Medical Research | 0.00% | -4.73% | +82.95% | +125.81% | -36.11% | 202M |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- ATOS Stock
- Charts Atossa Therapeutics, Inc.
- Comparison Chart